- Home
- RMMZ vs MGNX Comparison
RMMZ vs MGNX Comparison
Compare RMMZ & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMMZ | MGNX |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 220.6M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | RMMZ | MGNX |
|---|---|---|
| Price | $14.86 | $3.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 16.3K | ★ 726.6K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.83 | $1.19 |
| 52 Week High | $15.29 | $3.88 |
Technical Indicators
Market Signals| Indicator | RMMZ | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 47.85 |
| Support Level | $14.70 | $1.45 |
| Resistance Level | $14.84 | $3.26 |
| Average True Range (ATR) | 0.16 | 0.19 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 68.42 | 21.47 |
Price Performance
Historical ComparisonAbout RMMZ RiverNorth Managed Duration Municipal Income Fund II Inc.
RiverNorth Managed Duration Municipal Income Fund II Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About MGNX MacroGenics Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.